Fintel reports that on June 16, 2025, Truist Securities initiated coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation. Analyst Price Forecast Suggests 11.29% Upside As of June 1, 2025 ...

Fintel reports that on April 29, 2025, Wolfe Research downgraded their outlook for Insulet (NasdaqGS:PODD) from Outperform to Peer Perform. Analyst Price Forecast Suggests 24.18% Upside As of ...

INSULET CORP (PODD) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...

GEHC has seen stronger estimate revision activity and sports more attractive valuation metrics than PODD, so it seems like value investors will conclude that GEHC is the superior option right now.

HLN sticks out from PODD in both our Zacks Rank and Style Scores models, so value investors will likely feel that HLN is the better option right now.

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our P/B Growth Investor model based on the published strategy of ...

ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here.

ClearBridge Investments, an investment management firm, released its fourth-quarter 2023 “ClearBridge Aggressive Growth Strategy” investor letter, which can be downloaded here.

Insulet Corporation PODD shares traded lower Thursday. The stock has been under pressure this year amid the popularity of weight loss drugs. In addition to the effects of weight loss drug ...

Returning to the pre-inflation shock level of $318 means that PODD stock will have to gain more than 100% from here.